Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

"Newly observed in this study were the effects of LX4211, in healthy volunteers, of decreasing postprandial glucose levels without hypoglycemia and substantially reducing triglycerides," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Notably, the magnitudes of the reductions in triglycerides were similar to current standard of care prescription and clinical-stage medicines. By contrast, reported results of SGLT2-selective compounds have demonstrated minimal or no reductions in postprandial glucose in healthy subjects and minimal or no triglyceride decreases in either healthy normal volunteers or patients with type 2 diabetes."

Results from the study demonstrated that the 400 mg solid oral dose of LX4211 compared to placebo significantly reduced mean changes from baseline in fasting plasma glucose (p=0.005) and post-prandial glucose levels (p<0.001) in parallel with meaningful mean increases from baseline in total and active GLP-1 (p=0.055 and p=0.003, respectively) as well as PYY (p<0.001).  GLP-1 is associated with improved glucose control and decreased food intake through reduction of appetite.  PYY is a gas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... LONDRES, August 30, 2015 ... de l cuidado al paciente ... trayecto   Royal Philips  (NYSE: ... de IntelliSpace Cardiovascular , un sistema web de ... para acceder, analizar y compartir imágenes cardiovasculares e información ...
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... NEWTON, Mass., Nov. 3, 2010 Karyopharm Therapeutics Inc., a leader ... $20M Series A financing. The nuclear transport machinery plays an integral ... spectrum of human and animal disease. Karyopharm is focused on the ... i nhibitors of n uclear ...
... that a new market research report is available in its ... http://www.reportlinker.com/p0324749/Quality-for-Biologics.html Quality for Biologics – ... change control, product variation, characterisation, and regulatory concerns ... than sales of small molecule drugs, which grew by not ...
Cached Medicine Technology:Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 2Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 3Reportlinker Adds Quality for Biologics 2Reportlinker Adds Quality for Biologics 3Reportlinker Adds Quality for Biologics 4Reportlinker Adds Quality for Biologics 5Reportlinker Adds Quality for Biologics 6
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine ... At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle ... entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare ... hold down costs? , In a commentary for The American Journal of ... concept of “clinical efficacy,” which would bind parties together in agreements to intervene ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... at the 16th Innovations in Healthcare(SM) Awards Event , on October 21, ... (ABL) Organization , recognizes innovative organizations and individuals who are dramatically reducing the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
(Date:8/31/2015)... ... August 31, 2015 , ... DR. LUCIANA ON ... (aka Dr. Luciana) received a total of three Silver Medal awards at ... Best (Dis)ability Film. Dr. Luciana co-wrote and co-produced this pilot with Del Weston, ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Actor/Writer/Director/Psychology Professor Luciana Lagana Receives Three Wins at the 2015 Global Independent Film Awards for the TV Pilot Dr. Luciana on Aging and Falling 2
... , TUESDAY, Sept. 27 (HealthDay News) -- Rude employee ... from many businesses, a new U.S. study finds. ... said they,d experienced or witnessed insensitive, disrespectful or rude ... consumers said this incivility makes them less likely to ...
... rates linked to climate change will increase in several European ... study, which will be presented today (27 September 2011) at ... Belgium, France, Spain and Portugal will see the biggest climate-induced ... The research is part of the Climate-TRAP project and ...
... birth can have on the lungs of babies could be ... prematurely but may be reversed in their teenage years, according ... at the European Respiratory Society Annual Congress in Amsterdam today ... allows enough time for the infant to fully grow and ...
... Reporter , MONDAY, Sept. 26 (HealthDay News) -- U.S. health ... of blood clots in women taking newer forms of birth ... short of a definitive statement, the U.S. Food and Drug ... higher risk of blood clots in women taking the "fourth ...
... an ongoing debate: Should men over a certain age be ... treatments that may result in significant side effects if they ... by researchers at UCLA,s Jonsson Comprehensive Cancer Center has shown ... while patients with a single comorbid condition such as peripheral ...
... News) -- People with heart disease who undergo cardiac rehabilitation ... rate after exercise, a new study suggests. Researchers at ... recovery live longer than those whose hearts remain revved up ... that can do that," study author Dr. Leslie Cho, director ...
Cached Medicine News:Health News:Climate change set to increase ozone-related deaths over next 60 years 2Health News:Lung function of moderately premature babies is reduced at 8-9 years but may improve with age 2Health News:Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns 2Health News:Elderly patients may be undertreated for prostate cancer 2Health News:Elderly patients may be undertreated for prostate cancer 3Health News:Cardiac Rehab May Help Heart Patients Live Longer 2
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Convective Air Warming Blankets...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
Inquire...
Medicine Products: